Aikido Pharma (AIKI) Shares Have a Lot of Value Built in on Top of Near-Term Milestones Anticipated
AIKI Market cap is a ridiculous $10M less than cash on hand!
Just a move up to match the current book value of the company represents a 60% gain from the current PPS!!!
Good day everyone,
Continuing coverage of AIkido Pharma Inc. (NASDAQ: AIKI) recent corporate update here
Current price $1.09/share
AIKI shares showed resilience in Thursday’s session. The company shares closed at $1.07 in Wednesday’s session and closed yesterday at $1.09/share. After gaining 25% over the prior three sessions this week, some investors were inclined to take some profits and we congratulate them.
We believe the 7M shares traded yesterday represented most of the profit taking and the shares showed some strength as eager buyers kept the price firm. We believe AIKI shares could give real benefit to current shareholders as the stock approaches its book value of $1.73/share. We note a strong uptick in the last 30 minutes of Thursday’s session.
There are a few points from our reporting yesterday that we wanted to repeat:
The company had a cash and equivalents balance of $102 million or approximately $1.22 per share as of the last quarterly report in March.
CEO Anthony Hayes made three purchases of the company shares over the past 30 days, totaling 30,000 shares at the market price. The purchases increased Mr. Hayes holdings of AIKI shares by 60%. The fact that the AIKI CEO recently bought 30,000 shares at the market with his own funds can be quite telling. What does he know that we don’t? Everything.
In February, AIKI raised $75M in a share offering, a move that built the $100M pile of cash they are sitting on. Those shares were sold at $1.60, considerably higher than today’s price.
The AIKI pipeline:
DHA-dFdC (Gem-DHA) for oral and/or IV cancer treatment licensed from University of Texas at Austin.
The global gemcitabine market expected to reach $900M by 2027. Gem-DHA drug patent recently issued and expires in 2035. AIKI is collaborating with Parimer Scientific in South Carolina to manufacture the drug to FDA quality.
Synergistic dual drug radiotherapy for prostate cancer from Weill Cornell Medical School.
The global prostate cancer treatment market size is projected to reach $9,904 million by 2026. In February of this year, AIKI purchased an ownership interest in Convergent Therapeutics, Inc., which has licensed rights to this technology. This treatment uses two radioactive molecules to target PSMA receptor on cancer cells.
Clinical studies status:
Phase 1, 2a Single Ascending Dose CONV 01- completed
Phase 1b/2a Multiple Ascending Dose CONV 01- ongoing
Convergent is currently planning additional advanced human trials:
Phase 1b/2a with the combination of CONV 01-α and PSMA I&T-β;
Phase 2b with the combination of PSMA I&T-β ± CONV 01-α, and
Phase 1b/2a with PSMA I&T-α ± CONV 01-α (both drugs with 225Ac, the α-particle emitter)
Pan-Viral Drug Design licensed from University of Maryland at Baltimore.
Preliminary proof of concept against coronavirus, flu, Ebola, and others. The global flu drug market alone is projected to reach $993.7M by 2026.
SKI complex ID’d as a potential broad-spectrum antiviral target
• Initial data suggested functional link between viral proteins and SKI
• Computer modeling ID’d potential drug binding pockets on SKI
• Computer modeling to design compounds to bind SKI pockets
• Screening ID’d specific compounds that inhibit various viruses
• Inhibited viruses include influenza, Ebola, and Corona
Silo Pharma – Psylocybin Treatment in Cancer Patients.
Silo recently granted AIKI a worldwide exclusive, sublicensable, royalty-bearing license to four patent applications relating to delivering psilocybin directly to neuroinflamed tissue. Areas of potential use include treatment of cancer and symptoms caused by cancer, including but not limited to pain, nausea, neuroinflammation, brain and neural dysfunction, depression, seizures, confusion, dizziness, numbness/tingling, dysfunction of the senses and all other symptoms that are caused by cancer of any type.
UK G4-1 for Solid Tumor Treatment, University of Kentucky
Right to license and SRA to study 30-day survival in mice vs.
• Right to license lasts until 45 days after results reported to
us under SRA (extendable)
• Computer-designed drug isolated from ~340,000 candidates
• Effective against solid tumors, unlike competitors
• Excellent metabolic stability profile relative to competitors
• Works in cancers already resistant to competitor drugs
• Patent subject to our Option expires 2035
• Synthesis of drug to use in 30-day study almost complete
Wake Forest’s KPC34 for AML and ALL
• Licensed to KPC34 for treatment of Acute Myeloid Leukemia (AML) and Acute Myeloid
• Small target patient populations: AML ~21K new/yr and ALL ~6K/yr:
• Eligible for Orphan Drug Designation, providing 7 years market exclusivity
• KPC34 also based on gemcitabine, like UT’s DHA-dFdC
AIKI has an impressive pipeline with the potential for development in both oncology and anti virals. With these potential products, each capable of eventual market success, and the cash to make that happen, AIKI looks to be ready for a potential run.
Stay tuned and stay informed,
The Traders News Group
Do we disclose any information to outside parties?
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.